| Literature DB >> 34654719 |
Katie L Pennington1, Colten M McEwan1, James Woods1, Colin M Muir1, A G Pramoda Sahankumari1, Riley Eastmond1, Eranga R Balasooriya1, Christina M Egbert1, Sandeep Kaur2, Tyler Heaton3, Katherine K McCormack1, Stephen R Piccolo3, Manabu Kurokawa2, Joshua L Andersen4.
Abstract
PTOV1 is an oncogenic protein, initially identified in prostate cancer, that promotes proliferation, cell motility, and invasiveness. However, the mechanisms that regulate PTOV1 remain unclear. Here, we identify 14-3-3 as a PTOV1 interactor and show that high levels of 14-3-3 expression, like PTOV1, correlate with prostate cancer progression. We discover an SGK2-mediated phosphorylation of PTOV1 at S36, which is required for 14-3-3 binding. Disruption of the PTOV1-14-3-3 interaction results in an accumulation of PTOV1 in the nucleus and a proteasome-dependent reduction in PTOV1 protein levels. We find that loss of 14-3-3 binding leads to an increase in PTOV1 binding to the E3 ubiquitin ligase HUWE1, which promotes proteasomal degradation of PTOV1. Conversely, our data suggest that 14-3-3 stabilizes PTOV1 protein by sequestering PTOV1 in the cytosol and inhibiting its interaction with HUWE1. Finally, our data suggest that stabilization of the 14-3-3-bound form of PTOV1 promotes PTOV1-mediated expression of cJun, which drives cell-cycle progression in cancer. Together, these data provide a mechanism to understand the regulation of the oncoprotein PTOV1. IMPLICATIONS: These findings identify a potentially targetable mechanism that regulates the oncoprotein PTOV1. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34654719 PMCID: PMC8816884 DOI: 10.1158/1541-7786.MCR-20-1076
Source DB: PubMed Journal: Mol Cancer Res ISSN: 1541-7786 Impact factor: 6.333